KLOW is not a single peptide but a combination blend — a research “stack” that brings together four peptides studied for tissue repair and anti-inflammatory activity in one preparation.
What you’re reading about
KLOW combines four components:
- GHK-Cu — the copper tripeptide studied for skin and tissue repair. Read the GHK-Cu profile →
- BPC-157 — the pentadecapeptide studied for musculoskeletal and gut repair. Read the BPC-157 profile →
- TB-500 — the Thymosin β-4 fragment studied for cell migration and repair. Read the TB-500 profile →
- KPV — a melanocortin-derived tripeptide studied for anti-inflammatory signaling.
The rationale
The idea behind a blend like KLOW is complementary mechanisms: pairing peptides associated with angiogenesis, cell migration, extracellular-matrix synthesis, and inflammation control, so one preparation engages several arms of the repair process at once.
Research outlook
Because KLOW is a compounded combination, the blend itself has not been the subject of dedicated clinical trials — its rationale rests entirely on the research behind each component, which is why we link those profiles above. The one component without its own profile here is KPV, whose research centers on anti-inflammatory activity in models of gut and skin inflammation.
References
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
- Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides
- Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore
- Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model
- The neuroimmunomodulatory peptide alpha-MSH
